Mouse Monoclonal BCL2 Antibody

+ +

•  

   
     RN3L1 Antibody (C-term) (Cat. #P32167) western blot analysis in WiDr cell line lysates (35ug/lane).This demonstrates the RN3L1 antibody detected the RN3L1 protein (arrow).    

BCL2 (B-cell lymphoma 2) antibodies are essential tools for studying the role of the BCL2 protein, a key regulator of apoptosis. Initially identified in follicular lymphoma due to its association with the t(14;18) chromosomal translocation, BCL2 encodes an anti-apoptotic protein that prevents programmed cell death by inhibiting mitochondrial outer membrane permeabilization. Overexpression of BCL2 is linked to cancer development, therapy resistance, and poor prognosis, particularly in hematologic malignancies.

Antibodies targeting BCL2 (e.g., clones 100/D5. 124) are widely used in research and diagnostics. They help detect BCL2 expression via immunohistochemistry (IHC), Western blotting, or flow cytometry, aiding in lymphoma subtyping (e.g., distinguishing follicular lymphoma from reactive hyperplasia). Notably, different clones recognize distinct epitopes or isoforms, influencing specificity. For example, clone 124 detects both wild-type and fusion protein forms in formalin-fixed tissues, while clone 100/D5 may show variable sensitivity.

In clinical practice, BCL2 IHC is critical for identifying BCL2 overexpression in tumors, guiding differential diagnosis and therapeutic decisions. Recent studies also explore its role in solid tumors and interactions with pro-apoptotic proteins (e.g., BAX, BAK). However, interpretation requires caution, as normal lymphoid tissues and certain non-neoplastic cells may express BCL2. Emerging techniques, such as dual-staining with proliferation markers, enhance its utility in predicting tumor behavior. Therapeutic inhibitors like venetoclax (targeting BCL2) further underscore its biomedical relevance.